Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Sangamo Bioscienes Stock

Price
 
€9.98
-0.563
-5.340%
Target price
€13.98
19:45 / Tradegate WKN: 936386 / Symbol: SGMO / Name: Sangamo Biosci / Stock / Biotechnologie & medizinische Forschung
Latest predictions
€13.00
07.12.19
buy
€23.90
07.08.19
buy
€13.98
04.06.19
buy
€11.00
12.02.19
buy
€23.00
04.04.18
buy
Your prediction

Sangamo Bioscienes Stock

Sangamo Bioscienes took a tumble today and lost -€0.563 (-5.340%).
Our community is currently high on Sangamo Bioscienes with 5 Buy predictions and 0 Sell predictions.
With a target price of €13.00 there is a positive potential of 30.300% for Sangamo Bioscienes compared to the current price of €9.98.
Register To Post

Other discussions about Sangamo Bioscienes Stock

New thread

News

Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the first three patients treated in the Phase 1/2 THALES study evaluating

Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE), today announced updated follow-up results from the Phase 1/2 Alta study evaluating

Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. Sangamo

Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of James R. Meyers, an accomplished pharmaceutical executive with three decades of commercial

Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the United Kingdom’s (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted

Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at

Sangamo Therapeutics Reports Third Quarter 2019 Financial Results


Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported third quarter 2019 financial results and recent business highlights.



“We continue to prioritize and progress

Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting


Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will

Sangamo Therapeutics Announces New Scientific Advisory Board


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that is has established a new Scientific Advisory Board (SAB). The SAB comprises an eclectic group of industry

Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer


Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective October 31